Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31201339 | 0.80 | KDM4E (0.47) | KDM4EHTTMAPTLMNAALDH1A1 | |
| SCHEMBL21383755 | 0.73 | KDM4E (0.49) | KDM4EHTTMAPTLMNAALDH1A1 | |
| SCHEMBL5061012 | 0.73 | KDM4E (0.41) | KDM4EHTTMAPTLMNAALDH1A1 | |
| SCHEMBL31201372 | 0.73 | KDM4E (0.43) | KDM4EHTTMAPTLMNAALDH1A1 | |
| SCHEMBL23993919 | 0.73 | KDM4E (0.43) | KDM4EHTTMAPTLMNAALDH1A1 | |
| SCHEMBL2995450 | 0.69 | SMPD3 (0.39) | TDP1 | |
| SCHEMBL140145 | 0.68 | KDM4E (0.39) | KDM4EHTTMAPTLMNATDP1 | |
| SCHEMBL5061041 | 0.67 | KDM4E (0.38) | KDM4EHTTMAPTLMNAALDH1A1 | |
| SCHEMBL31201312 | 0.65 | KDM4E (0.45) | KDM4EHTTMAPTALDH1A1HPGD | |
| SCHEMBL105123 | 0.65 | BAZ2B (0.41) | KDM4EHTTMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727944-A1 | [1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Perha Pharmaceuticals (FR) | 2026-04-22 | — | — | EP | disclosed |
| US-20250275965-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| WO-2025080788-A1 | CCR4 INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024256496-A1 | [1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES USEFUL AS A MEDICAMENT | PERHA PHARMACEUTICALS (FR) | 2024-12-19 | — | — | WO | disclosed |
| EP-4477653-A1 | [1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Perha Pharmaceuticals (FR) | 2024-12-18 | — | — | EP | disclosed |
| CN-116888126-A | Compound of casein kinase inhibitor | 北京原基华毅生物科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022127755-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127755-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2018086585-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | 山东罗欣药业集团股份有限公司 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275965-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | PACSIN2, CSNK1A1, CSNK1G3 | KDM4E 1702/4885HTT 3664/4885MAPT 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.